The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex

The Effect of Caloric and Non-caloric Sweeteners on Hunger, Gastrointestinal Hormones as Well as on Antral and Duodenal Motility

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02891525

Enrollment

Registered

2016-09-07

Start date

2015-03-31

Completion date

Unknown

Last updated

2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

In this study, the investigators aimed at evaluating the role of sweet taste receptors in the gastrointestinal tract (GIT). Intragastric administration of glucose, fructose or acesulfame-K were compared with placebo administration for their effects on gastrointestinal motility, gut hormone release (motilin, ghrelin, glucagon-like peptide-1 (GLP-1) and insulin) and hunger feelings.

Interventions

DIETARY_SUPPLEMENT50g glucose

DIETARY_SUPPLEMENT25g fructose

DIETARY_SUPPLEMENT220mg acesulfame-K

DIETARY_SUPPLEMENT250mL tap water

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI\<30 kg/m² for the lean volunteers * Female or male subjects aged 18 to 60 * Subject is capable and willing to give informed consent * Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception

Exclusion criteria

* Female volunteer is pregnant or breastfeeding * GI diseases, major abdominal surgery * Volunteers that have food allergies, especially fructose intolerance * Major psychiatric illnesses * Volunteers that use drugs affecting the GI tract or the central nervous system * Volunteers suffering from an endocrine disease such as diabetes, Cushing's disease, Addison's disease, hypothalamic tumor * Volunteers that have undergone surgical procedure for weight loss

Design outcomes

Primary

Measure	Time frame
Change in gastrointestinal motility measured by antroduodenal high-resolution manometry	3 hours after administration, continuous measurement with high resolution manometry

Secondary

Measure	Time frame
Change in gut hormone release measured by specific radioactive immunoassays	3 hours after administration, blood sample every 15 min
Change in subjective hunger and satiety scores measured by visual analogue scales of 100 mm	3 hours after administration, assessment every 5 min

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026